Previous close | 132.37 |
Open | 131.57 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 1100 |
Day's range | 131.07 - 133.75 |
52-week range | 72.39 - 138.28 |
Volume | |
Avg. volume | 5,088,493 |
Market cap | 595.278B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 48.86 |
EPS (TTM) | 2.72 |
Earnings date | N/A |
Forward dividend & yield | 1.37 (1.03%) |
Ex-dividend date | 22 Mar 2024 |
1y target est | 139.70 |
Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.
Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the programme i
In this article, we will be taking a look at the 20 most overweight states in the US. If you do not wish to learn about the global obesity market, head straight to the 5 Most Overweight States in the US. In the United States, the issue of obesity remains a significant public health concern, […]